S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:RVMD

Revolution Medicines (RVMD) Stock Forecast, Price & News

$30.00
-0.48 (-1.57%)
(As of 09/22/2023 ET)
Compare
Today's Range
$29.60
$30.48
50-Day Range
$25.17
$35.05
52-Week Range
$17.39
$35.50
Volume
1.82 million shs
Average Volume
1.11 million shs
Market Capitalization
$3.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.57

Revolution Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
18.6% Upside
$35.57 Price Target
Short Interest
Bearish
11.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
-0.31mentions of Revolution Medicines in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.46) to ($3.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

894th out of 968 stocks

Biological Products, Except Diagnostic Industry

146th out of 160 stocks


RVMD stock logo

About Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Price History

RVMD Stock News Headlines

U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Revolution Medicines (NASDAQ: RVMD)
The Latest Analyst Ratings for Revolution Medicines
Q1 2023 Revolution Medicines Inc Earnings Call
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
292
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.57
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+18.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-248,710,000.00
Net Margins
-1,003.36%
Pretax Margin
-1,004.78%

Debt

Sales & Book Value

Annual Sales
$35.38 million
Book Value
$7.72 per share

Miscellaneous

Free Float
99,891,000
Market Cap
$3.28 billion
Optionable
Not Optionable
Beta
1.36
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Mark A. Goldsmith Ph.D. (Age 61)
    CEO, Pres & Chairman
    Comp: $1.05M
  • Mr. Jack AndersMr. Jack Anders (Age 46)
    Chief Financial Officer
    Comp: $544.8k
  • Ms. Margaret A. Horn J.D. (Age 60)
    Chief Operating Officer
    Comp: $775.6k
  • Dr. Stephen M. Kelsey FRC Path. (Age 62)
    FRCP, M.D., Pres of R&D
    Comp: $779k
  • Ms. Xiaolin WangMs. Xiaolin Wang (Age 52)
    Exec. VP of Clinical Devel.
    Comp: $604.1k
  • Dr. Martin D. Burke M.D.
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael A. Fischbach Ph.D. (Age 42)
    Academic Co-Founder & Member of Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Academic Co-Founder & Member of Scientific Advisory Board
  • Mr. Walter Reiher Ph.D.
    Chief Information Officer
  • Ms. Jan Smith Ph.D.
    Chief Scientific Officer













RVMD Stock - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price forecast for 2023?

7 brokerages have issued 12-month price objectives for Revolution Medicines' stock. Their RVMD share price forecasts range from $23.00 to $47.00. On average, they anticipate the company's stock price to reach $35.57 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2023?

Revolution Medicines' stock was trading at $23.82 on January 1st, 2023. Since then, RVMD stock has increased by 26.1% and is now trading at $30.04.
View the best growth stocks for 2023 here
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.10. The firm had revenue of $3.82 million for the quarter, compared to analyst estimates of $1.56 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 36.46%. The business's revenue for the quarter was down 58.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.82) earnings per share.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

What is Revolution Medicines' stock symbol?

Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.56%), BVF Inc. IL (5.73%), Bellevue Group AG (4.35%), State Street Corp (4.35%), JPMorgan Chase & Co. (3.63%) and Woodline Partners LP (3.45%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revolution Medicines' stock price today?

One share of RVMD stock can currently be purchased for approximately $30.04.

How much money does Revolution Medicines make?

Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $3.28 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis.

How many employees does Revolution Medicines have?

The company employs 292 workers across the globe.

How can I contact Revolution Medicines?

Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.

This page (NASDAQ:RVMD) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -